Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
Atogepant had substantially lower numbers needed to treat and costs per additional responder versus placebo than rimegepant for the preventive treatment of EM across all evaluated scenarios. These analyses suggest that atogepant may be more cost effective than rimegepant for the preventive treatment of EM. Limitations include differences in inclusion/exclusion criteria and in reporting of the ≥50% responder rates between trials.
Authors
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Rashmi B. Halker Singh (ORCID: https://orcid.org/0000-0002-4280-4440)
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Stephanie J. Nahas (ORCID: https://orcid.org/0000-0001-8846-8393)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Amber Trujillo Lalla (ORCID: https://orcid.org/0000-0003-4267-1374)
- Natty Chalermpalanupap
- Kari Kelton (ORCID: https://orcid.org/0000-0002-2692-4899)
- Jonathan H. Smith
- Peter McAllister (ORCID: https://orcid.org/0000-0003-4965-7700)
Institutions
- Thomas Jefferson University (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- AbbVie (United States) (US)
- Medical Decision Modeling (United States) (US)
- Mayo Clinic in Arizona (US)
- New England Institute for Neurology and Headache (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/head.14824
- Citations
- 5
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.93
Funders
- AbbVie